[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Wright State University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":285},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,42,68,88,110,131,152,172,191,214,244,263],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100643030","phase-1-pilot-studies-testing-the-use-of-oral-amitriptyline-in-reducing-localized-burn-injury-induced-microvesicle-particle-release-100643030",false,"NCT07640061","Pilot Studies Testing the Use of Oral Amitriptyline in Reducing Localized Burn Injury-induced Microvesicle Particle Release","Inclusion Criteria:\n\n* Adult Males and Females age 18 - 60\n* All skin types on Fitzpatrick Scale (Type I-VI)\n* Able to comprehend procedures and risks\n* Willing to participate and understand the informed consent document\n* Have reliable transportation\n\nExclusion Criteria:\n\n* Subjects should be otherwise healthy and not have any significant medical issues that could interfere with the study, in particular any heart arrythmias and not be on any prescription medications that could react with amitriptyline.\n* History of abnormal scarring (i.e., keloids) or poor wound healing.\n* No over the counter non-steroidal anti-inflammatory agents (aspirin, acetaminophen) or antioxidant vitamins (vitamin C) in past 14 days.\n* Currently taking known photosensitizers, anti-inflammatories, other tricyclic antidepressants, or systemic agents known to be aSMase inhibitors\n* Large tattoos in designated testing areas\n* Tanning bed use within last 3 months\n* UVB treatments in past 3 months\n* Medical history of abnormal scarring or diseases that could affect wound healing\n* Medical history of hypertension\u002Fhypotension or heart problems\n* Pregnant or nursing\n* History of sores in nares or easy bleeding from nares or other bleeding disorders.\n* Nasal piercings\n* Known allergies to lidocaine or amitriptyline",true,"ALL","18 Years","60 Years",{"count":20,"type":21},20,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","The purpose of this study is to determine the amount of substances contained in skin known as microvesicle particles (MVP). The hypothesis to be tested in this study is that treatment with a single dose of 75mg of amitriptyline will block the MVP released from the skin from a very small localized burn injury.",[27,28],"Microvesicle Particles","Thermal Burn","NOT_YET_RECRUITING","2026-06-04",{"date":32,"type":33},"2026-06-10","ACTUAL",{"date":35,"type":21},"2027-06",{"date":37,"type":21},"2033-06",{"name":39,"class":40},"Wright State University","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":50,"briefSummary":52,"conditions":53,"keywords":56,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":41},"100601892","phase-4-intranasal-sphenopalatine-ganglion-blockade-for-headaches-following-aneurysmal-subarachnoid-hemorrhage-100601892","NCT07116408","Intranasal Sphenopalatine Ganglion Blockade for Headaches Following Aneurysmal Subarachnoid Hemorrhage","Intranasal Sphenopalatine Ganglion Blockade as a Non-invasive, Opioid-sparing Treatment for Headaches Following Aneurysmal Subarachnoid Hemorrhage","Inclusion Criteria:\n\n• Patients aged 18 years or older who are being treated in the neurologic ICU for subarachnoid hemorrhage with Hunt and Hess scale of 0-3 (Scale ranges from 0 to 5 with higher numbers indicating more severe symptoms) and able to verbally report headache will be considered for inclusion in this study.\n\nExclusion Criteria:\n\n* Patients under the age of 18 years of age.\n* Patients with an allergy to lidocaine.\n* Patients from all vulnerable groups.\n* Patients with Hunt and Hess scale score of 4-5. (Scale ranges from 0 to 5 with higher numbers indicating more severe symptoms.)\n* Patients who are not able to consent.\n* Mentally impaired patients that are unable to provide consent.\n* Patients that are prisoners.\n* Pregnant patients.\n\nAdditionally, patients with contraindications to use of the Tx 360 device will be excluded. Contraindications include:\n\n* History of recurrent nose bleeds.\n* Nasal septal deformity such as cleft lip and palate, choanal atresia (narrowed nasal passages), atrophic rhinitis, rhinitis medicamentosa, septal perforation, nasal\u002Fmidface trauma.\n* Recent nasal\u002Fsinus surgery\n* Presence of a bleeding disorder (eg., Von Willebrand's disease or hemophilia).\n* Severe respiratory distress.\n* Presence of angiofibroma, sinus tumor, or granulomatous disease of the nasopharynx.\n* Presence of nasal trauma.\n* Nasal congestion that has been present more than 10 days, high fever, or abnormal appearance of the nasal mucosa or mucus.",{"count":20,"type":21},[51],"PHASE4","In patients with bleeding from a brain aneurysm, severe headache is the most common complaint. However, the pain is difficult to treat. The use of standard pain medications is common, but pain control remains poor. Additionally, pain medicines have multiple side effects including sedation, interference with breathing, intestinal cramping, low blood pressure, and the risk of addiction. In the present study, the investigators will examine the use of a medication to block the sphenopalatine ganglion which is a bundle of nerves that includes nerves that cause head pain. This block is performed by spraying numbing medication into the back of the nasal cavity on both sides. This particular pain medication does not have the side effects discussed above. The purpose of the study is to see if this treatment will decrease pain without causing unwanted side effects.\n\nAll patients in the study will receive standard pain medicine as needed for headache. Information will be collected from the patient's medical chart on the amount of pain medication used and the amount of pain the patient describes having. The average pain will be calculated for the first 24 hours the patient is in the hospital. At that point, the patient will receive pain medication sprayed into the back of the nasal cavity on both sides. Patients will also receive this treatment 3 days later. Following these treatments, information will be obtained on the average amount of pain, and how much other pain medication is used.\n\nThe investigators will look at the amount of pain and the amount of other pain medicine used over the first 24 hours before the nasal pain medicine treatment and compare it to the time after the treatments to see if the amount of pain decreases and if the amount of other pain medicine needed decreases as well. Six months after discharge, the patient will be contacted by phone to find out more information about how much head pain they had after discharge from the hospital.",[54,55],"Aneurysmal Subarachnoid Hemorrhage (aSAH)","Headache",[55,57,58],"subarachnoid hemorrhage","aneurysm","RECRUITING","2026-05-21",{"date":62,"type":33},"2026-05-27",{"date":64,"type":33},"2024-05-20",{"date":66,"type":21},"2027-05",{"name":39,"class":40},{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":22,"phases":75,"briefSummary":77,"conditions":78,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":41},"100553685","mechanisms-for-laser-induced-rejuvenation-100553685","NCT06489301","Mechanisms for Laser-Induced Rejuvenation","Inclusion Criteria:\n\n* Adult males and females 18 and older\n* Able to comprehend procedures and risks\n* Planning to undergo abdominoplasty surgery\n* Minimum amount of skin to be removed is 50 x 20cm\n\nExclusion Criteria:\n\n* Medical history of not well-controlled diabetes. This is defined as a subject who needs high doses of insulin, recent history of hospitalization for diabetes-related complications, or poor wound health as evidenced by diabetic ulcers. Subjects who have been deemed healthy enough for abdominoplasty surgery would tend to suggest that their diabetes should not be an issue. However, if the subjects have diabetic complications as outlined above, they could affect the wound healing which is the object of this protocol so they would be excluded.\n* Pregnant or nursing\n* History of pathologically abnormal wound healing such as keloidal scars\n* Existing tattoos on the abdomen that are so extensive that they could interfere with the study",{"count":5,"type":21},[76],"NA","It has shown that laser wounding of geriatric skin protects it against skin cancer. The purpose of this study is to determine the origin of cells called fibroblasts which are present after treatment with Fractionated Laser Resurfacing (FLR). These cells restore a youth-like ultraviolet B (UVB) response, but where they come from is currently unknown. The study recruits subjects who are scheduled to undergo abdominoplasties to investigate the origin of those cells stimulated by laser treatment.",[79],"Skin Cancer","2026-05-18",{"date":82,"type":33},"2026-05-22",{"date":84,"type":33},"2025-07-16",{"date":86,"type":21},"2028-12",{"name":39,"class":40},{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":4,"eligibilityCriteria":94,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":95,"targetDuration":4,"studyType":22,"phases":97,"briefSummary":99,"conditions":100,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":41},"100540128","phase-2-evaluating-use-of-topical-imipramine-and-amitriptyline-in-reducing-ultraviolet-b-light-induced-redness-in-patients-with-rosacea-100540128","NCT06312813","Evaluating Use of Topical Imipramine and Amitriptyline in Reducing Ultraviolet B Light-Induced Redness in Patients With Rosacea","Pilot Studies Evaluating Use of Topical Imipramine and Amitriptyline in Reducing Ultraviolet B Light-Induced Redness in Patients With Rosacea","Inclusion Criteria:\n\n* Fitzpatrick Skin Type I - IIII\n* Self-identified rosacea or no history of flushing\u002Fblushing for controls\n* Able to provide medical history and list of medications -- control subjects will not be allowed to take medications that are known to be photosensitizers.\n\nExclusion Criteria:\n\n* Using imipramine, amitriptyline or any other tricyclic antidepressant (oral or topical)\n* Using topical anti-inflammatory (within 1 week) or systemic agents (e.g. prednisone)\n* Large tattoos in the designated testing areas\n* Tanning bed use within last 3 months\n* Photodynamic Therapy or UCB treatments in past 3 months\n* Female Subjects: pregnant or nursing",{"count":96,"type":21},48,[98],"PHASE2","Rosacea is a common skin condition associated with easy blushing and red face; many patients with rosacea react to sunlight with increased redness. The purpose of this study is to determine if the use of a topical medication will help reduce sunlight induced redness and irritation in patients with rosacea.",[101],"Rosacea","2026-02-17",{"date":104,"type":33},"2026-02-18",{"date":106,"type":33},"2024-02-27",{"date":108,"type":21},"2028-12-01",{"name":39,"class":40},{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":22,"phases":118,"briefSummary":120,"conditions":121,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":41},"100365279","early-phase-1-triamcinolone-with-vitamin-d-synergistic-efficacy-in-psoriasis-100365279","NCT04036188","Triamcinolone With Vitamin D Synergistic Efficacy in Psoriasis","Inclusion Criteria:\n\n* Age 18 and older\n* Mild to severe plaque psoriasis (2% or greater Body Surface Area; Psoriasis Area and Severity Score of 2 or greater; Investigator Grade Assessment of mild-severe)\n\nExclusion Criteria:\n\n* Currently taking medication that alters the normal ion balance of low-dose in blood.\n* No calcium supplements 1 month prior to baseline (not including multivitamins).\n* Unstable or uncontrolled illness, including but not limited to cerebro-cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic, neurologic or psychiatric disease at screening.\n* Abnormal laboratory values at screening, that in the opinion of the investigator, would potentially affect patient safety or data integrity.\n* Not on systemic non-biologic therapy (including, but not limited to, oral psoralen plus ultraviolet A \\[photochemotherapy (PUVA)\\] light therapy; cyclosporine; corticosteroids; methotrexate; oral retinoids; apremilast; tofacitinib; mycophenolate mofetil; thioguanine; hydroxyurea; sirolimus; tacrolimus; azathioprine; leflunomide; fumaric acid derivatives; or 1, 25 dihydroxy vitamin D3 and analogues) within 28 days prior to baseline.\n* No phototherapy (including either oral and topical PUVA light therapy, ultraviolet B, excimer laser, or self-treatment with tanning beds or therapeutic sunbathing) within 28 days prior to baseline.\n* No topical treatment (including, but not limited to, corticosteroids \\[upper mid strength or lower potency topical steroids are permitted on the intertriginous areas and face\\], crisaborole, anthralin, calcipotriene, topical vitamin D derivatives, retinoids, tazarotene, pimecrolimus, tacrolimus, emollients and other nonprescription topical products containing urea, \\>3% salicylic acid, alpha- or beta-hydroxyl acids, or medicated shampoos \\[for example those that contain \\>3% salicylic acid, corticosteroids, coal tar, or vitamin D3 analogues\\]) within 14 days prior to baseline.\n* No biologic agents within 8 weeks or three half-lives, whichever is greater prior to baseline.\n* History of renal impairment.\n* History of renal stones.\n* History of parathyroid abnormalities\n* Osteoporosis\n* History of severe arthritis\n* Ongoing use of tanning bed or other UV device or excessive sunlight\n* Unable to understand\u002Fcomplete informed consent.",{"count":117,"type":21},24,[119],"EARLY_PHASE1","These studies are designed to assess the synergistic efficacy of topical 0.1% triamcinolone cream paired with 40,000 IU of oral vitamin D3 daily in treating mild to moderate psoriasis. The study is designed to have all subjects treated with triamcinolone cream (TAC) for 4 weeks, then will be randomized 1:1 into vitamin D3 or placebo for an additional 12 weeks. At that time, the study will become open-label and all subjects will be placed on (or continue) vitamin D3 for an additional 12 weeks. The study will take place over 28 weeks total.",[122,123],"Plaque Psoriasis","Vitamin D3",{"date":125,"type":33},"2026-02-19",{"date":127,"type":33},"2019-10-16",{"date":129,"type":21},"2026-12",{"name":39,"class":40},{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":16,"minAge":18,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":22,"phases":139,"briefSummary":140,"conditions":141,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":151,"locationsCount":41},"100355308","effectiveness-of-fractionated-laser-resurfacing-to-protect-geriatric-skin-from-actinic-neoplasia-100355308","NCT03906253","Effectiveness of Fractionated Laser Resurfacing to Protect Geriatric Skin From Actinic Neoplasia","Inclusion Criteria:\n\n* Diagnosed with Actinic Keratosis within the past 6 months\n* At least 60 years of age, or older\n* Ability to comprehend procedures and risks versus benefits\n* Able to provide Informed Consent\n* Fair Skin (Fitzpatrick Type I or II)\n* Possess both Right and Left Forearms\n\nExclusion Criteria:\n\n* Uncontrolled Diabetes Mellitus\n* Not able to comprehend procedures or risks versus benefits\n* Pregnant or nursing\n* Large tattoos on forearms\n* History of abnormal healing or scarring (i.e., keloids)\n* Any disease that gets worse while in the sun\n* Use of topical or oral anti-inflammatory medication or steroids\n* Allergy to lidocaine\n* Current use of photosensitizing medication",{"count":138,"type":21},72,[76],"This study is following up on previous studies that have demonstrated that geriatric subjects respond different to ultraviolet B (UVB) light than young subjects. The treatment of geriatric skin with dermal rejuvenation therapies (dermabrasion, fractionated laser resurfacing) restores the appropriate UVB response. Ongoing studies have tested the ability of fractionated laser resurfacing (FLR) to assess how long this wounding effect lasts-and have found that this appears to be a durable response which lasts for at least two years. The findings that FLR protects geriatric skin at two years is the impetus for this study.\n\nThis study is an interventional study to assess if FLR treatment of one forearm of geriatric subjects with multiple actinic keratosis will result in the short-term removal of actinic keratosis, and the long-term decrease in levels of future actinic keratosis and other non-melanoma skin cancers in comparison to the untreated arm.\n\nStudy length and visit: The first part of the study is completed in 1 day then there are follow up visits at 90 days and every 6 months for 5 years.",[142,143,144],"Actinic Keratoses","Aging","Non-Melanoma Skin Cancer","2025-03-24",{"date":147,"type":33},"2025-03-25",{"date":149,"type":33},"2018-01-10",{"date":86,"type":21},{"name":39,"class":40},{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":4,"eligibilityCriteria":158,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":159,"enrollmentInfo":160,"targetDuration":4,"studyType":22,"phases":161,"briefSummary":162,"conditions":163,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":41},"100371905","dna-repair-activity-in-the-skin-of-day-and-night-shift-workers-100371905","NCT04122456","DNA Repair Activity in the Skin of Day and Night Shift Workers","Pilot Study on DNA Repair Activity in the Skin of Day and Night Shift Workers","Inclusion Criteria:\n\n* Male\u002FFemale\n* Fair skin (Fitzpatrick types I and II)\n* Age 18 to 40\n* Able to comprehend procedures\u002Frisks\n* Primarily work and are awake during normal daylight hours (6 am to 6 pm), or primarily work and are awake during night shifts hours (between the hours of 6 pm and 6 am) or may work a mixture of these shifts over the past 3 months. Rotating shifts will be categorized based on the majority of hours worked on average during the last 3 months. Able to fill out a 3-month calendar of work schedule.\n\nExclusion Criteria:\n\n* Known photosensitivity\n* Currently on photosensitizing medications\n* Diabetes Mellitus\n* On any hormonal agents (e.g., birth control pills)\n* History of abnormal scarring\n* History of skin infections\n* History of skin cancers\n* History of sleep disorders such as sleep apnea or insomnia\n* Known allergy to lidocaine local anesthetic\n* Pregnancy or nursing\n* Other serious health issues","40 Years",{"count":96,"type":21},[76],"The purpose of this study is to test how the skin of night shift workers responds to artificial sunlight (ultraviolet B radiation; UVB) at two different times of the day in comparison to normal day shift workers. After the skin biopsies are obtained, they will be brought to the laboratory to be exposed to UVB radiation and to measure UVB responses.",[79],"2025-02-05",{"date":166,"type":33},"2025-02-06",{"date":168,"type":33},"2022-12-07",{"date":170,"type":21},"2025-12",{"name":39,"class":40},{"id":173,"slug":174,"hasResults":11,"nctId":175,"briefTitle":176,"officialTitle":177,"acronym":4,"eligibilityCriteria":178,"healthyVolunteers":15,"sex":16,"minAge":179,"maxAge":4,"enrollmentInfo":180,"targetDuration":4,"studyType":22,"phases":181,"briefSummary":182,"conditions":183,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":186,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":190,"locationsCount":41},"100357294","early-phase-1-gene-expression-changes-in-young-and-geriatric-skin-100357294","NCT03932162","Gene Expression Changes In Young and Geriatric Skin","Gene Expression Changes in Young and Geriatric Skin","Inclusion Criteria:\n\n* Male\u002FFemale\n* White skin (Fitzpatrick types I and II)\n* Age 21-30 or 65 and older\n* Able to comprehend procedures\u002Frisks\n\nExclusion Criteria:\n\n* Known photosensitivity\n* Currently on photosensitizing medications\n* Diabetes Mellitus\n* History of abnormal scarring\n* History of skin infections\n* Known allergy to lidocaine local anesthetic\n* Pregnancy or nursing\n* Other serious health issues","21 Years",{"count":117,"type":21},[119],"This study does not involve any particular diagnosis. The goal of this research study is to explore the effects of artificial sunlight (ultraviolet B radiation; UVB) on the skin of young adults versus geriatric adults. Sunlight exerts many effects on the body. There is evidence that in response to ultraviolet B radiation (UVB), which are the burning rays of sunlight, young adult skin responds differently than geriatric skin. In fact, researchers feel that this difference in how the skin reacts to UVB is why skin cancers are found in older skin. Researchers believe that a major difference between young adult and geriatric skin is that young skin has a lot of a protein called insulin-like growth factor-1 (IGF-1), whereas geriatric skin has very little. The current study will test how young adult versus geriatric skin responds to UVB, and if geriatric skin treated with an injection of small amount of IGF-1 drug will then act like young skin.",[184,185,143],"UVB Phototherapy Burn","Insulin-like Growth Factor 1",{"date":166,"type":33},{"date":188,"type":33},"2019-09-06",{"date":170,"type":21},{"name":39,"class":40},{"id":192,"slug":193,"hasResults":11,"nctId":194,"briefTitle":195,"officialTitle":196,"acronym":4,"eligibilityCriteria":197,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":198,"enrollmentInfo":199,"targetDuration":4,"studyType":22,"phases":201,"briefSummary":202,"conditions":203,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":41},"100402434","phase-1-testing-use-of-topical-imipramine-in-reducing-ultraviolet-b-induced-microvesicle-particle-release-in-photosensitive-subjects-100402434","NCT04520217","Testing Use of Topical Imipramine in Reducing Ultraviolet B Induced Microvesicle Particle Release in Photosensitive Subjects","Pilot Studies Testing Use of Topical Imipramine in Reducing Ultraviolet B Induced Microvesicle Particle Release in Photosensitive Subjects","Inclusion Criteria:\n\n* Female and Male adult subjects age 18 to 50\n* Must be able to give informed consent\n* Have access to stable transportation\n* All skin types on Fitzpatrick Scale (Type I-VI)\n* Self-Identified photosensitivity\n* Able to provide medical history and list of medications-control subjects will not be allowed to be taking a medication that is known to be photosensitizer.\n\nExclusion Criteria:\n\n* Underlying diseases that could affect wound healing (e.g., uncontrolled diabetes mellitus)\n* Taking medications that are known photosensitizers (e.g., doxycycline) or anti-inflammatories (e.g., NSAIDS \\[except for low-dose aspirin\\] or steroids)\n* Utilizing imipramine or any other tricyclic antidepressant (oral or cream)\n* Utilizing topical anti-inflammatory or systemic agents (e.g., prednisone)\n* Large tattoos in the designated testing areas\n* Tanning bed use within last 3 months\n* Photodynamic Therapy or UVB treatments in past 3 months\n* Female Subjects: pregnant or nursing\n* History of abnormal scarring (i.e., keloids)","50 Years",{"count":200,"type":21},40,[24],"The purpose of this study is three-fold. First, researchers will assess whether subjects who have clinically abnormal reactions to sunlight (photosensitivity) have increased levels of microvesicle particles (MVP) following ultraviolet B (UVB) treatment to localized area of skin. Second, researchers will assess if topical application of the medicine imipramine will block UVB-induced MVP release. Third, researchers will assess if the topical cream will block UVB-induced increased erythema reactions (reddening of the skin).",[204,205],"Photosensitivity","Microvesicle Particle","2025-01-24",{"date":208,"type":33},"2025-01-27",{"date":210,"type":33},"2022-06-06",{"date":212,"type":21},"2026-12-01",{"name":39,"class":40},{"id":215,"slug":216,"hasResults":11,"nctId":217,"briefTitle":218,"officialTitle":218,"acronym":219,"eligibilityCriteria":220,"healthyVolunteers":11,"sex":16,"minAge":179,"maxAge":4,"enrollmentInfo":221,"targetDuration":4,"studyType":22,"phases":223,"briefSummary":224,"conditions":225,"keywords":231,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":243},"100561973","ai-augmented-motivational-interviewing-training-for-primary-care-100561973","NCT06597123","AI-Augmented Motivational Interviewing Training for Primary Care","AIM-PC","Inclusion Criteria:\n\n* Primary care providers (physicians, physician assistants, and nurse practitioners) employed in primary care practices of the Premier Physician Network of Premier Health (southwest Ohio) are eligible to participate.\n\nExclusion Criteria:\n\n* Eligible PCPs who opt to not provide informed consent for participation will be excluded from the study.",{"count":222,"type":21},150,[76],"This study will examine the impact of training primary care providers (PCPs) in motivational interviewing (MI) using artificial intelligence (AI) to augment the training process. MI is a patient-centered approach to engaging patients in their own care. There will be a control group and two intervention groups, with the intervention groups receiving a different amount of MI training. The hypothesis is that the AI-augmented MI training will result in improved patient outcomes, improved clinician wellbeing, and reduced behavioral manifestation of clinician biases. This mixed-methods project will also collect qualitative data from structured interviews and focus groups with participating PCPs to examine perceived facilitators and barriers to the use of the MI approach in primary care.",[226,227,228,229,230],"Multiple Chronic Conditions","Patient Engagement","Burnout, Professional","Motivational Interviewing","Implicit Bias",[229,232,226,233,234,227],"Artificial Intelligence","Clinician Wellbeing","Biases","2024-09-12",{"date":237,"type":33},"2024-09-19",{"date":239,"type":21},"2025-07-01",{"date":241,"type":21},"2028-06-30",{"name":39,"class":40},2,{"id":245,"slug":246,"hasResults":11,"nctId":247,"briefTitle":248,"officialTitle":248,"acronym":4,"eligibilityCriteria":249,"healthyVolunteers":11,"sex":16,"minAge":18,"maxAge":4,"enrollmentInfo":250,"targetDuration":4,"studyType":22,"phases":252,"briefSummary":253,"conditions":254,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":262,"locationsCount":41},"100549031","the-preventive-role-of-fractionated-laser-resurfacing-against-actinic-neoplasia-in-an-at-risk-geriatric-population-100549031","NCT06428721","The Preventive Role of Fractionated Laser Resurfacing Against Actinic Neoplasia in an At-Risk Geriatric Population","Inclusion Criteria:\n\n* Adult Males and Females aged 60 and older\n* Have at least 5 AKs on each forearm\u002Fwrist, but no more than 10 to allow for easy monitoring\n* Skin type fair (Fitzpatrick I-II)\n* Females must be post-menopausal and not be on systemic hormone replacement therapy\n* Able to comprehend procedures and risks\n\nExclusion Criteria:\n\n* More than 10 AKs on an extremity\n* AKs that are large (2-3+, hyperkeratotic grade 3 lesions)\n* AKs that are very thick (\\>3 mm)\n* Medical history of diabetes\n* History of poor wound healing or scarring\n* Large tattoos that can interfere with study\n* Other serious health issues and other skin diseases that could interfere with the study\n* Recent (within 1 year) field therapies such as efudex cream or PDT to forearms\u002Fwrists.\n* Planning to leave region in next 5 years\n* Subjects with allergies to xylocaine will be excluded if they need this topical anesthetic.",{"count":251,"type":21},80,[76],"The purpose of this study is to determine if the Fractionated Laser Resurfacing (FLR) procedure can protect one forearm\u002Fwrist from precancerous actinic keratosis (AKs) as well as prevent skin cancer in older subjects with active AKs. This study builds on a similar study ongoing at the Dayton Veterans Administration dermatology clinic. This study is also testing if a photograph of the skin can be used to predict where the AKs and an skin cancers will form.",[142,143,144],"2024-07-23",{"date":257,"type":33},"2024-07-24",{"date":259,"type":33},"2024-03-20",{"date":261,"type":21},"2031-12",{"name":39,"class":40},{"id":264,"slug":265,"hasResults":11,"nctId":266,"briefTitle":267,"officialTitle":268,"acronym":4,"eligibilityCriteria":269,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":270,"targetDuration":4,"studyType":22,"phases":271,"briefSummary":272,"conditions":273,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":278,"startDateStruct":280,"completionDateStruct":282,"leadSponsor":284,"locationsCount":41},"100492189","phase-1-the-effect-of-topical-imipramine-on-pain-and-effectiveness-of-topical-photodynamic-therapy-100492189","NCT05688904","The Effect of Topical Imipramine on Pain and Effectiveness of Topical Photodynamic Therapy","Pilot Studies Testing the Effect of Topical Imipramine on Pain and Effectiveness of Topical Photodynamic Therapy","Inclusion Criteria:\n\n* Male or female ages 18 and older\n* Skin type must be \"Fair\", Fitzpatrick type I to III, due to the presence of actinic damage in this population.\n* Subjects need to have a physician's order to receive PDT treatment on their face, scalp or forearms.\n* Willing to participate and understand the informed consent document.\n* Willing to avoid excess sun exposure\u002Ftanning beds to the area to be treated with PDT.\n\nExclusion Criteria:\n\n* Those currently taking any tricyclic antidepressants (TCAs)\n* Those currently taking any selective serotonin reuptake inhibitor (SSRI)\n* Those with porphyria\n* Large tattoos in the treated areas\n* Pregnancy or nursing\n* Taking any oral or topical medications that could interfere with the PDT (Appendix A)\n* Active rashes in the area",{"count":117,"type":21},[24],"The purpose of this study is testing the use of topical Imipramine in combination with topical photodynamic therapy's (PDT) effect on pain following treatment. PDT is a commonly used treatment in dermatology for patients who have many pre-cancers (actinic keratosis-AKs) on their skin. These are both FDA-approved treatments, but this study is evaluating their use in combination, which has not been evaluated in the past. The investigators have been doing studies using animals that suggest that imipramine might make the PDT less painful and might help it work better. In order to participate, the subject and their dermatologist have decided that they would benefit from PDT to treat their skin due to many AK precancerous lesions. Please note that neither PDT nor imipramine are experimental treatments, but treating their skin with imipramine before PDT is a new approach.",[274,275,276],"Imipramine","Photodynamic Therapy","Actinic Keratosis","2024-04-23",{"date":279,"type":33},"2024-04-24",{"date":281,"type":33},"2023-01-19",{"date":283,"type":21},"2028-03",{"name":39,"class":40},""]